Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE)

NCT01744470 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

286

Enrollment

OTHER

Sponsor class

Conditions

De Novo Transplant Disease

Interventions

DRUG: Tacrolimus targeted half-dose
DRUG: Tacrolimus targeted plain dose

Sponsor

University Hospital, Tours

Collaborators

[object Object]